An Off Broadway play opens a window on the spiritual and physical trials of the ancient Japanese sport.

Read reviews for The Public Theater and Ma-Yi Theater Company’s New York premiere of SUMO, a new play written by Lisa Sanaye ...

Penciled by TONY MOORE, TOM FOWLER, LAN MEDINA, DECLAN SHALVEY, THONY SILAS, KIM JACINTO & ARIEL OLIVETTI with HUMBERTO RAMOS, STEFANO CASELLI, LEE GARBETT, SANA TAKEDA, JULIAN TOTINO TEDESCO ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

and a grant from the Takeda Science Foundation. The researchers also made use of facilities at the SLAC National Accelerator Laboratory in California, which is supported by the U.S. Department of ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other Japanese stocks. As the dangers of natural disasters increase and ...